

BOARD AND MANAGEMENT UPDATE

- **Experienced biotechnology executive & cell therapy specialist Dr Bradley Glover appointed Non-Executive Chair**
- **Mr Phillip Hains retires as CFO and Joint Company Secretary**
- **Mr Aaron Laurita appointed as Chief Financial Officer**

Sydney, Australia, 16 February 2026: Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, is pleased to announce updates to its Board of Directors and Management team.

As part of the Board refresh announced on 28 November 2025, the Board conducted a global recruitment process that identified over 30 potential Chair candidates. This was narrowed to several candidates, all of whom presented to the independent Non-Executive Directors, and the Company is pleased to announce that Dr Bradley Glover has been appointed as Non-Executive Director and Chair effective today.

Dr Glover is an accomplished biotechnology executive with over 20 years of leadership experience across global biopharmaceuticals, cell therapy, biomaterials, and life sciences, spanning both public and private companies.

Dr Glover brings deep expertise in cell and gene therapy, corporate development, and capital formation, with a strong track record of executing value-creating strategic transactions, while leading organisations through critical clinical, operational and commercial inflection points. Dr Glover has advanced autologous and allogeneic CAR-T and NK cell therapy programs across hematologic malignancies and solid tumors, from early development through commercialisation.

Dr Glover has held senior leadership roles at Imugene, Celularity, Kite Pharma, Genentech, Roche, and Illumina, with responsibilities spanning corporate strategy, corporate development, manufacturing expansion, supply chain, and commercial launch execution — including the launches of YESCARTA® and TECARTUS™.

He brings a rare blend of operating, strategy, and capital markets experience, with a track record of working closely with boards and investors on value creation, capital allocation, and execution through inflection points. Dr Glover also serves on several other boards including Lamorinda Therapeutics and Basilard BioTech.

Dr Glover holds a degree in biochemistry from the University of California San Diego, a PhD from the University of Colorado in biochemistry and molecular genetics and an MBA from the Rady School of



Management at UCSD. He was also a Jane Coffin Childs Medical Research Fellow at the University of California Berkeley.

Phillp Hains, Acting Chair, said: “Brad brings a unique skillset at this crucial time in the Company’s development. He has strong experience in cell therapies plus extensive global networks into large pharma to complement Rebecca and her team.”

Mr Hains will continue to serve as a Non-Executive Director for a period, and will step down from his roles as Joint Company Secretary and Chief Financial Officer, effective 16 February 2026.

The Company has also appointed Mr Aaron Laurita as Chief Financial Officer, effective today.

Mr Laurita brings strong finance and commercial expertise to Chimeric, developed through working with organisations across several sectors, including the biotechnology sector, in Australia, the United States and Canada over the past decade.

Mr Laurita holds a Bachelor of Business (Professional Accountancy) from RMIT University and is a qualified Chartered Accountant and a member of Chartered Accountants Australia and New Zealand.

Mr Nathan Jong continues as Company Secretary and person responsible for communication with ASX in relation to listing rule matters under Listing Rule 12.6.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

Chimeric’s world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.



CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

Authorised on behalf of the Chimeric Therapeutics Board of Directors.

Contact

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: investors@chimerictherapeutics.com

W: www.chimerictherapeutics.com

Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: matt@nwrcommunications.com.au